From Medscape Oncology

Coverage from the

American Society of Hematology (ASH) 2016 Annual Meeting

December 03 - 06, 2016; San Diego, California

December 03 - 06, 2016 San Diego, California

Stopping Drug Therapy for CML: EURO-SKI Results This is the largest cohort to date of patients with chronic myeloid leukemia followed after stopping treatment with tyrosine kinase inhibitors.
Medscape Medical News, December 5, 2016
ASH CAR T Cells Motoring to Market -- by Next Year? Pivotal registration trials for CAR T cell therapies have now been completed, and two products could be approved by the end of 2017.
Medscape Medical News, December 5, 2016
ASH Obinutuzumab Bests Rituximab in Advanced FL Obinutuzumab for induction and maintenance was better than the current standard of care for follicular lymphoma, but caution is warranted with chemotherapy used as part of induction.
Medscape Medical News, December 5, 2016

Meeting Highlights at a Glance

Top News From ASH 2016: Slideshow Practice-changing research in lymphoma and leukemia, plus growing excitement over two chimeric antigen receptor (CAR) T cell products, featured prominently at this year's meeting.

Conference News

ASH Bendamustine Toxicity in FL Raises Eyebrows -- and Questions
Medscape Medical News, December 19, 2016
ASH Largest Trial of Transplants in Myeloma: No Need for Extras
Medscape Medical News, December 15, 2016
ASH 'Meaningful' Responses With Ibrutinib in Chronic GVHD
Medscape Medical News, December 15, 2016
ASH CPX-351: Better Outcomes in Older High-Risk AML Patients
Medscape Medical News, December 14, 2016
ASH Thrombosis Risk With PICC in Critically Ill Children
Medscape Medical News, December 8, 2016
ASH Cutting Dose, Instead of Stopping Therapy, in Patients With CML
Medscape Medical News, December 5, 2016
ASH Mortality Plummets in Pregnant Women With Sickle Cell Disease
Medscape Medical News, December 5, 2016
ASH CAR T Cells Motoring to Market -- by Next Year?
Medscape Medical News, December 5, 2016

ASH Obinutuzumab Bests Rituximab in Advanced FL
Medscape Medical News, December 5, 2016
ASH Novel Agent Reduces Pain Crises in Sickle Cell Anemia
Medscape Medical News, December 4, 2016
ASH Rituximab Maintenance Ups Survival in MCL After Transplant
Medscape Medical News, December 4, 2016
ASH Maintenance Lenalidomide Prolongs PFS in High-Risk CLL
Medscape Medical News, December 4, 2016
ASH For Trauma Use -- Dried Blood Powder, Just Add Water
Medscape Medical News, December 3, 2016
ASH Superior Outcomes With Brentuximab in Cutaneous T Cell Lymphoma
Medscape Medical News, December 3, 2016
ASH What's Hot at ASH 2016 Meeting?
Medscape Medical News, November 29, 2016

Popular ASH 2015 News

Gene Therapy Is 'Becoming a Clinical Reality' After setbacks that included leukemia in treated patients, there is now enthusiasm for a new approach to gene therapy using lentiviral vectors.
Medscape Medical News, Dec 17, 2015
Three-Drug Combo Now Standard in Newly Diagnosed Myeloma Data from the first randomized trial in newly diagnosed multiple myeloma should convince the skeptics that remain about the superiority of a triplet.
Medscape Medical News, Dec 7, 2015
CLL Patients With 'Dismal' Prognosis Respond to Venetoclax Venetoclax shows impressive responses in patients with relapsed/refractory CLL who harbor the 17p deletion and who tend to have worse prognoses.
Medscape Medical News, Dec 10, 2015

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Expert Updates from ASH 2016 Coverage of key advances and expert reactions as they happened at the meeting.

Medscape Oncology Insights

New CML Data Post Signs on Route to Treatment-Free Remission
Theodore Bosworth
In the Era of Novel Therapies, New CLL Markers Required
Theodore Bosworth
Cellular Immunotherapy for Multiple Myeloma Advancing Rapidly
Theodore Bosworth
At ASH, New Approaches Suggest 'Major Advances' Against AML
Joseph G. Jurcic, MD
Negative Trials, CAR T Studies Lead ASH Lymphoma Highlights
Ann S. LaCasce, MD, MSc;
Kerry Savage, MD
Myeloma Data at ASH 2016 Focus on Novel Combinations
Saad Z. Usmani, MD

Pre-Meeting Commetary

ASH16 Preview: New CAR T-cell Data Come at a Pivotal Moment
Miguel-Angel Perales, MD

Previous Coverage